82
Participants
Start Date
April 30, 2002
Primary Completion Date
January 31, 2004
Study Completion Date
January 31, 2004
Degarelix
One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
Degarelix
One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
Degarelix
One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
Degarelix
One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
Drs. Werner, Murdock & Francis, PA, Greenbelt
Pinellas Urology, Inc., St. Petersburg
SW Florida Urological Associates, Fort Myers
Urology Specialists of Oklahoma, Inc., Tulsa
Urology Clinics of NorthTexas, PA, Dallas
Urology San Antonio Research, San Antonio
Urology Associate PC', Denver
Nevada Urology Associates, Reno
Western Clinical Research, Torrance
San Bernardino Urological Associates Medical Group, San Bernardino
South Orange County Medical Research Center, Laguna Woods
Advanced Urology Medical Center, Anaheim
Lead Sponsor
Ferring Pharmaceuticals
INDUSTRY